Fair Value Measurements - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) shares
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock, shares outstanding (in shares) | shares	551,281,154		522,817,137
Contingent consideration	$ 550		$ 48,949
Gain (loss) on derivative liability	(1,280)	$ 7,500
Private Placement Warrants
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Gain (loss) on derivative liability	$ (1,300)
Class A Common Stock | Celularity
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock, shares outstanding (in shares) | shares	20,422,124
Effective Debt Yield
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input	0.163
Risk Adjusted Net Sales Forecast
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input	0.065
ACEA Therapeutics, Inc
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Contingent consideration	$ 52,200
Gain (Loss) on re-measurement of fair value	$ (3,800)
Fair Value, Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Contingent consideration
ACEA Therapeutics, Inc | Effective Debt Yield
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input	0.213